Press release
CD Bioparticles Launches Innovative Organoid Construct Kit to Advance Drug Discovery
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its Organoid Construct Kits [https://www.cd-bioparticles.net/medical-device] to the scientific community to facilitate the construction of complex organoid models, enabling researchers to advance drug discovery and development, disease modeling, and personalized medicine.
Organoids are microscopic organ-like structures derived from stem cells that have become powerful tools for studying disease mechanisms, drug efficacy and toxicity. CD Bioparticles now offers a variety of Organoid Construction Kits to simplify the process of generating organoids and enable scientists to accelerate their research. This comprehensive portfolio of Organoid Construction Kits includes Cervical Cancer Organoid Construct Kit, Gastric Cancer Organoid Construction Kit, Intestinal Organoid Construction Kit, Lung Cancer Organoid Construction Kit, and Ovarian Cancer Organoid Construction Kit.
These kits include a complete set of optimized reagents, protocols and technical support to guide users through the entire organoid construction process. For example, the ready-to-use Intestinal Organoid Construction Kit can maximize the the satisfaction of customer's experimental needs, provide the greatest convenience, and reduce the time spent on non-experimental processes. The Organoid Construction Kit is divided into four modules: Part I: Tissue Dissociation and Organoid Construction; Part II: Organoid Transfer; Part III: Organoid Freezing; and Part IV: Organoid Recovery.
The products provide customers with consumables and reagents needed for the entire experimental process, saving time wasted in purchasing various reagents and consumables. Customers only need to equip the product with routine instruments and consumables to complete the entire experimental process of intestinal cancer organoid construction. With its user-friendly protocol and high-quality components, researchers can now streamline their organoid development process and achieve reproducible results.
The Organoid Construction Kit is the latest addition to CD Bioparticles' extensive portfolio of drug delivery products and services. The company also offers a wide range of 3D cell culture substrates, engineered tissue scaffolds, and other biomaterials for various applications in drug delivery, diagnostics, and research. With these tools, the company can provide researchers with custom solution to the challenges they often face in creating optimal cell growth environments, acquiring sufficient lab materials, and developing biocompatible support structures for tissue regeneration.
In addition, CD Bioparticles offers specialized delivery techniques, tissue engineering scaffold design and modification, and advanced technology platforms to accelerate research. The new products reflect the company's commitment to providing cutting-edge tools that support scientists in their endeavors to advance biomedical research and empower researchers to explore the complexities of human biology and develop novel therapeutic approaches.
CD Bioparticles is dedicated to delivering quality solutions to meet the evolving needs of the scientific community. For more information about the Organoid Construct Kits, please visit https://www.cd-bioparticles.net/medical-device.
About CD Bioparticles
CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.
Media Contact
Company Name: CD Bioparticles
Contact Person: Richard J. Gray
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cd-bioparticles-launches-innovative-organoid-construct-kit-to-advance-drug-discovery]
State: New York
Country: United States
Website: https://www.cd-bioparticles.net/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CD Bioparticles Launches Innovative Organoid Construct Kit to Advance Drug Discovery here
News-ID: 3636725 • Views: …
More Releases from ABNewswire
Alopecia Areata Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial U …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Alopecia Areata pipeline constitutes 18+ key companies continuously working towards developing 20+ Alopecia Areata treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Alopecia Areata Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
How A Certified C3PAO Streamlines Compliance And Reduces Risk?
In the complex ecosystem of government contracting, cybersecurity compliance, specifically achieving the Cybersecurity Maturity Model Certification (CMMC), is no longer a suggestion; it's a mandate that dictates your eligibility for crucial defense contracts.
Image: https://www.abnewswire.com/upload/2025/10/a953b43e8195b4c7cb1199c1cd374ce0.jpg
You're aware of just how overwhelming it can be trying to thread your way through the labyrinth of security controls and documentation requirements that seem to suck whatever time and funds you've got available. This distracts you…
Acquired Hemophilia A Pipeline 2025: Comprehensive Clinical Trials and Therapies …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acquired Hemophilia A pipeline constitutes 10+ key companies continuously working towards developing 10+ Acquired Hemophilia A treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Acquired Hemophilia A Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acquired Hemophilia A Market.
The…
Achondroplasia Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial P …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Achondroplasia pipeline constitutes 5+ key companies continuously working towards developing 5+ Achondroplasia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Achondroplasia Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/achondroplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Achondroplasia Market.
The Achondroplasia Pipeline report embraces in-depth commercial and clinical…
More Releases for Organoid
4Dcell Achieves 95% Organoid Reproducibility Breakthrough With Patented Anchorin …
4Dcell announced that its SmartSphero plates have achieved over 95% reproducibility in organoid size and shape, while reducing organoid loss during medium exchanges to below 12%, a significant improvement over the 86% loss seen in traditional unanchored systems. This breakthrough addresses a persistent challenge in pharmaceutical drug screening and safety testing, where inconsistent organoid cultures have often hindered data reliability.
The company's patented Anchoring Point Technology (APT®) allows researchers to culture…
Organoid Culture Medium Research:the global Organoid Culture Medium market size …
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Organoid Culture Medium- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years.
…
Organoid Technology Market Size, Growth, In-depth Analysis, Research Report Fore …
The organoid technology market is estimated to grow at a CAGR of 27.12% during the forecast period.
The prime factors propelling the growth of the organoid technology market are increasing demand for personalized medicine, drug discovery and development, and regenerative medicine.
As per the report, the organoid technology market is expected to grow rapidly during the forecast period.
Organoids are three-dimensional cell cultures that mimic the structure and function of human organs, making…
Organoid Technology Market Trends, Future Demands, Growth Factors, Emerging Tech …
The global Organoids and Spheroids Market size was valued at $516.6 million in 2021 and is projected to reach $1.2 billion by 2031, growing at a CAGR of 8.5% from 2022 to 2031.
Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers.
Between traditional two-dimensional cell…
Organoids Market Driven By Definigen, Organoid Therapeutics, Hubrecht Organoid T …
The scope of the organoids market includes type, application, source, and region. The organoids market is analyzed based on regions, such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the organoids market emphasizing on various parameters, such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe.…
Organoids Market Witness Heightened Revenue of US$ 3,420.40 million by 2027 with …
The Organoids Market was valued at US$ 689.47 million in 2019 and it is projected to reach US$ 3,420.40 million by 2027; it is expected to grow at a CAGR of 22.1% from 2020 to 2027.
Organoids are tiny, self-organized three-dimensional tissue cultures that are derived from stem cells. Such cultures can be crafted to replicate much of the complexity of an organ, or to express selected aspects of it like…
